Your browser doesn't support javascript.
loading
Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery.
Müller, Andrea M; Schmohl, Kathrin A; Knoop, Kerstin; Schug, Christina; Urnauer, Sarah; Hagenhoff, Anna; Clevert, Dirk-André; Ingrisch, Michael; Niess, Hanno; Carlsen, Janette; Zach, Christian; Wagner, Ernst; Bartenstein, Peter; Nelson, Peter J; Spitzweg, Christine.
Affiliation
  • Müller AM; Department of Internal Medicine II, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
  • Schmohl KA; Department of Internal Medicine II, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
  • Knoop K; Department of Internal Medicine II, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
  • Schug C; Department of Internal Medicine II, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
  • Urnauer S; Department of Internal Medicine II, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
  • Hagenhoff A; Clinical Biochemistry Group, Medizinische Klinik und Poliklinik IV, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
  • Clevert DA; Department of Clinical Radiology, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
  • Ingrisch M; Department of Clinical Radiology, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
  • Niess H; Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
  • Carlsen J; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
  • Zach C; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
  • Wagner E; Department of Pharmacy, Center of Drug Research, Pharmaceutical Biotechnology, Ludwig Maximilian University of Munich, Munich, Germany.
  • Bartenstein P; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
  • Nelson PJ; Clinical Biochemistry Group, Medizinische Klinik und Poliklinik IV, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
  • Spitzweg C; Department of Internal Medicine II, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.
Oncotarget ; 7(34): 54795-54810, 2016 Aug 23.
Article de En | MEDLINE | ID: mdl-27458162
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Symporteurs / Cellules souches mésenchymateuses / Radio-isotopes de l'iode / Tumeurs du foie / Tumeurs expérimentales du foie Type d'étude: Prognostic_studies Limites: Animals / Female / Humans Langue: En Journal: Oncotarget Année: 2016 Type de document: Article Pays d'affiliation: Allemagne
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Symporteurs / Cellules souches mésenchymateuses / Radio-isotopes de l'iode / Tumeurs du foie / Tumeurs expérimentales du foie Type d'étude: Prognostic_studies Limites: Animals / Female / Humans Langue: En Journal: Oncotarget Année: 2016 Type de document: Article Pays d'affiliation: Allemagne